



23 December 2022

## NON-RENOUNCEABLE PRO-RATA RIGHTS ISSUE OFFER

**Melbourne, Australia – Opyl Limited (ASX:OPL)** is pleased to announce a non-renounceable rights issue, to raise up to \$480,390 (Offer) (further details of which are set out below). This offer is not underwritten.

The funds raised from the placement and rights issue will be applied to:

- Accelerating the conversion of the sales pipeline
- Development and release of additional functionality on Opin that provides for greater automation connecting patients to trial sites, supporting scale and additional income stream
- Expansion of Opin into key APAC markets (NZ, Korea and Taiwan) and first entry into US markets
- Ongoing product development and enhancement
- Working capital

The Company is inviting shareholders to participate in the OPL non-renounceable pro-rata entitlement offer of one (1) New Share for every four (4) Shares held at the Record Date of 3 January 2023, at an Issue Price of \$0.03 per New Share (Offer).

If the Rights Issue is fully subscribed for by Eligible Shareholders the Company will raise \$480,390 and issue a further approximately 16,013,013 Shares.

The Company expects to make offers to all Eligible Shareholders with a registered address in Australia or New Zealand who hold Shares as at 7pm (AEDT) on the Record Date of Friday, 30 December 2022.

Shareholders who, at the Record Date, have an address registered in either Australia, will be eligible to participate in the Offer. All other shareholders will not be eligible to participate.

New Shares issued pursuant to the Offer will rank equally with existing fully paid ordinary shares currently on issue and the Company will apply to ASX for official quotation of the New Shares.

Eligible Shareholders may also apply for additional new shares (Additional New Shares), being New Shares in excess of their pro rata entitlement under the Offer. The allocation of Additional New Shares and any scale back will be subject to availability of Additional New Shares and will occur in the Company's absolute discretion.

Any New Shares offered under the Rights Issue that are not subscribed for by Eligible Shareholders will form part of the shortfall (Shortfall). The Directors reserve the right, subject to the Corporations Act and the Listing Rules, to allocate any Shortfall to Eligible Shareholders that apply for Additional New Shares or otherwise, to place any remaining Shortfall at their discretion within 3 months after the Closing Date (on the same conditions as New Shares including the issue of Rights Options and at a price not less than the Issue Price).



## Timetable

The Offer is proposed to be conducted according to the following timetable:

Lodgement of Appendix 3B and Cleansing Notice for Rights Issue with ASX	Before open of ASX trade, Wednesday, 28 December 2022
"Ex" Date (i.e. the date on and from which Shares trade on ASX without an Entitlement)	Friday, 30 December 2022
Record Date (i.e. the time and date for determining Entitlements)	7pm (Melbourne time) on Tuesday, 3 January 2023
Despatch of the Rights Issue Offer Document and Entitlement & Acceptance Form to Eligible Shareholders and announcement to ASX that this despatch has occurred.	Tuesday, 3 January 2023
Opening Date of Rights Issue Offer.	Tuesday, 3 January 2023
Last day to Extend Entitlement Offer close date	12pm (Melbourne time) on Tuesday, 24 January 2023
Closing Date for acceptances under the Rights Issue Offer	5pm (Melbourne time) on Monday, 30 January 2023
Shortfall (if any) announced to the ASX	Wednesday, 1 February 2023
Issue of the New Rights Issue Shares	Wednesday, 1 February 2023
Trading (T+2) of New Shares expected to commence	Friday, 3 February 2023
Trading in New Shares on ASX	Friday, 3 February 2023

All dates (other than the date of lodgement of the Offer Document with ASX) are indicative only. The Company reserves the right, subject to the Corporations Act, the ASX Listing Rules



and other applicable laws, to vary the dates of the Offer, including extending the Closing Date or accepting late acceptances, either generally or in particular cases, without notice.

The Board has authorised this announcement for release to the ASX.

**-ENDS-**

For media and investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)

For clinical trial recruitment enquiries: [info@opin.ai](mailto:info@opin.ai)

[www.opyl.ai](http://www.opyl.ai)

[www.opin.ai](http://www.opin.ai)

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook